MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 09 Sep 2018
At a glance
- Drugs Trastuzumab (Primary) ; Tucatinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms MOUNTAINEER
- 31 Aug 2018 Biomarkers information updated
- 15 May 2018 Planned End Date changed from 30 Jun 2020 to 30 Jun 2021.
- 09 Mar 2018 According to a Seattle Genetics media release, Cascadian Therapeutics has been acquired by Seattle Genetics, and this acquisition provides the Global Rights of Tucatinib to Seattle Genetics.